Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 7/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24174326 | 1.00 | PARP1 (0.42) | PARP1DRD3CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL30421259 | 1.00 | PARP1 (0.42) | PARP1DRD3CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL23959359 | 0.84 | KDM4E (0.43) | PARP1DRD3KEAP1NFE2L2KDM4E | |
| SCHEMBL30422185 | 0.84 | KDM4E (0.43) | PARP1DRD3KEAP1NFE2L2KDM4E | |
| SCHEMBL24174302 | 0.84 | KDM4E (0.43) | PARP1DRD3KEAP1NFE2L2KDM4E | |
| SCHEMBL30422600 | 0.83 | HTR2C (0.45) | PARP1ALDH1A1KDM4EMAPT | |
| SCHEMBL24174623 | 0.83 | HTR2C (0.45) | PARP1ALDH1A1KDM4EMAPT | |
| SCHEMBL23959518 | 0.83 | HTR2C (0.45) | PARP1ALDH1A1KDM4EMAPT | |
| SCHEMBL9913091 | 0.81 | PRCP (0.52) | CYP2C9CYP2C19ALDH1A1NPSR1KEAP1 | |
| SCHEMBL30952112 | 0.81 | PRCP (0.52) | CYP2C9CYP2C19ALDH1A1NPSR1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4139295-B1 | ISOQUINILINE NRF2 AGONISTS | C4X DISCOVERY LTD (GB) | 2025-04-09 | — | — | EP | disclosed |
| EP-4252755-A2 | THERAPEUTIC COMPOUNDS | C4x Discovery Limited (GB) | 2023-10-04 | — | — | EP | disclosed |
| EP-3870578-B1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LTD (GB) | 2023-08-16 | — | — | EP | disclosed |
| US-20230159511-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4X DISCOVERY LIMITED (GB) | 2023-05-25 | — | — | US | disclosed |
| US-20230159511-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4X DISCOVERY LIMITED (GB) | 2023-05-25 | — | — | US | disclosed |
| US-20230159511-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4X DISCOVERY LIMITED (GB) | 2023-05-25 | — | — | US | disclosed |
| US-20220002286-A1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LIMITED (GB) | 2022-01-06 | — | — | US | disclosed |
| WO-2021214472-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4X DISCOVERY LIMITED (GB) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159511-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | PARP1 950/4885DRD3 3750/4885CYP2C9 1200/4885 |
| US-20220002286-A1 | THERAPEUTIC COMPOUNDS | NFE2L2, KEAP1, NQO1 | PARP1 1632/4885DRD3 4066/4885CYP2C9 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.